Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0725

+3.6%

Oct 31 3:52 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	10/3/2014 4:40:53 PM
	Read Replies (1) of 13111

I missed these words in my original posting of today's news. IMO these are important words. ************************** Progression-free survival in the All Lesions Treated group was 9.8 months. In the uninjected Bystander Lesion group from the original trial, progression-free survival was 8.9 months. This finding helped the investigators finalise the trial design for a phase 3 study. “Based on these data,” Dr. Agarwala said, “we will treat all lesions in the phase 3 trial, and include only BRAF wild-type patients (who do not respond to BRAF inhibitors) and those who have become refractory to systemic immunotherapy or are not candidates because of advanced age or comorbidities.” “We should see a difference very quickly between PV-10 and chemotherapy responses,” Dr. Agarwala added. Approximately 1 third of patients with melanoma are diagnosed with predominantly locoregional disease.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next